Abstract
Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Congenital thrombophilia is a condition that predisposes to a higher incidence of VTE and often requires long-term anticoagulation for secondary prophylaxis. It is less clear the efficacy of DOACs in patients with major thrombophilia. The aim of our study was to evaluate the efficacy and safety of full and reduced DOACs dose for VTE secondary prophylaxis, in patients affected by major congenital thrombophilia compared to a control group of patients with idiopathic recurrent VTE without thrombophilia. We retrospectively evaluated consecutive patients who required long-term anticoagulation for recurrent VTE, treated with DOACs, and compared the outcomes between patients affected by major thrombophilia and the control group. The examined patients were 209. The median time of DOACs therapy was 20 months (range 6–90). Two (2.7%) thrombotic events were observed in the subset affected by major congenital thrombophilia (n = 72) and five (3.6%) in the control group (n = 137) (p 0.73). Four (5.5%) hemorrhagic events were reported in the group with major thrombophilia; 21 (15.3%) in the other group (p 0.039). No statistically significant differences were observed in terms of efficacy and safety between DOACs at full and reduced dose. Our data suggest that DOACs may be effective and safe in the secondary VTE prophylaxis in patients affected by major congenital thrombophilia, also at reduced dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352. https://doi.org/10.1016/j.chest.2015.11.026
Zuk J, Papuga-Szela E, Zareba L, Undas A (2021) Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. Int J Hematol 113(2):190–198. https://doi.org/10.1007/s12185-020-03012-7 (Epub 2020 Oct 11. Erratum in: Int J Hematol. 2021 Jan 5: PMID: 33040276)
Krumb E, Hermans C (2021) Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia. Res Pract Thromb Haemost 5(2):261–264. https://doi.org/10.1002/rth2.12479 (PMID: 33733024; PMCID: PMC7938623)
Serrao A, Lucani B, Mansour D, Ferretti A, Baldacci E, Santoro C, Foà R, Chistolini A (2019) Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterr J Hematol Infect Dis. https://doi.org/10.4084/mjhid.2019.044 (PMID: 31308920; PMCID: PMC6613626)
Campello E, Spiezia L, Simion C, Tormene D, Camporese G, Dalla Valle F, Poretto A, Bulato C, Gavasso S, Radu CM, Simioni P (2020) Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Assoc. https://doi.org/10.1161/JAHA.120.018917 (Epub 2020 Nov 23. PMID: 33222589; PMCID: PMC7763770)
Margaglione M, Antonucci E, D’Andrea G, Migliaccio L, Ageno W, Bucherini E, Cosmi B, Falanga A, Martini G, Mastroiacovo D, Paparo C, Poli D, Testa S, Palareti G (2020) Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. Blood Transfus 18:486–495. https://doi.org/10.2450/2020.0091-20
Serrao A, Ballotta L, Dragoni F, Pallotta A, Chistolini A (2020) Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia. Thromb Res 196:539–540. https://doi.org/10.1016/j.thromres.2020.10.020 (Epub 2020 Oct 20. PMID: 33126052)
Valanejad SM, Kyle AD (2021) Direct oral anticoagulants in select patients with hypercoagulable disorders. Ann Pharmacother 55(7):891–901. https://doi.org/10.1177/1060028020968551 (Epub 2020 Oct 26. PMID: 33100017)
Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38:496–520. https://doi.org/10.1200/JCO.19.01461
Wypasek E, Potaczek D, Alhenc-Gelas M, Undas A (2014) PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. Thromb Res 134:199–201. https://doi.org/10.1016/j.thromres.2014.01.023 (Epub 2014 Jan 23 PMID: 24507871)
Aryal MR, Gosain R, Donato A, Yu H, Katel A, Bhandari Y et al (2019) Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 15:2381–2387. https://doi.org/10.1182/bloodadvances.2019000572
Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A et al (2015) Comparison of the novel oral anticoagulants, apixaban, dabigatran, edoxaban and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE 10:1–14. https://doi.org/10.1371/journal.pone.0144856
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author(s) declared they do not have any potential conflicts of interest.
Ethical approval
No ethics approval was sought for this retrospective analysis.
Human and animal rights
The study was conducted in compliance with Institutional Review Board/Human Subjects Research Committee requirements.
Informed consent
This study was a retrospective analysis, all the patients signed the informed consent to the treatment and to the use of their clinical data for scientific purposes.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Serrao, A., Assanto, G.M., Mormile, R. et al. Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients. Intern Emerg Med 17, 1081–1085 (2022). https://doi.org/10.1007/s11739-021-02917-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-021-02917-3